AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)
An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 and Standard First Line Treatment (BAT) in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study
Sponsor: AOP Orphan Pharmaceuticals AG
This PHASE3 trial investigates Polycythemia Vera and is currently completed. AOP Orphan Pharmaceuticals AG leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AOP Orphan Pharmaceuticals AG
- PharmaEssentia Corporation (for the U.S.)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Banská Bystrica, Slovakia , Barcelona, Spain , Bonn, Germany , Brasov, Romania , Bratislava, Slovakia , Brno, Czechia , Bucharest, Romania , Budapest, Hungary , Cherkasy, Ukraine and 34 more locations